Skip to content

Released Nov 9, 2026, before the open

10-Q filed Nov 9, 2026, 40 days after period end · 0001193125-26-452699

Q3 2026 · 10-Q
Revenue$207.86M+1.1% vs Q3 2025−1.5% vs Q2 2026
Net Income-$6.07MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$0.15N/M vs Q3 2025N/M vs Q2 2026
Gross Profit$146,546,000−1.3%
Operating Income$1,545,000N/M
Operating Cash Flowderived$363,000−97.1%
Free Cash Flowderived-$14,139,000N/M
Margins · derived
Gross margin70.5%−1.7 pt vs Q3 2025
Operating margin0.7%+9.0 pt vs Q3 2025
Net margin-2.9%+8.2 pt vs Q3 2025

What the release said

Orthofix revised its full-year 2026 guidance, with net sales now expected at $825 million to $830 million, down from $845 million to $855 million, and adjusted EBITDA at $86 million to $88 million, down from $95 million to $98 million.123

For the third quarter of 2026, net sales were $207.9 million, up 1.1% on a reported basis, and reported net loss was $(6.1) million, or $(0.15) per share, compared with $(22.8) million, or $(0.57) per share, a year earlier.45

Non-GAAP adjusted EBITDA was $26.0 million, or 12.5% of pro forma net sales, in the third quarter of 2026, compared with $24.6 million, or 12.1% of pro forma net sales, in the third quarter of 2025.5

Global Spine Fixation 1 net sales increased 1%, Global Limb Reconstruction net sales increased 8% on a reported basis, and Therapeutic Solutions net sales increased 4% compared with the prior year period.678

Cash, cash equivalents, and restricted cash totaled $86.9 million at September 30, 2026, compared with $104.4 million at June 30, 2026.9

Q3 2026 reported net sales
$207.9 million4
Q3 2026 reported net loss
$(6.1) million5
Q3 2026 non-GAAP adjusted EBITDA
$26.0 million5
Revised full-year 2026 net sales guidance
$825 million to $830 million pro forma net sales guidance, compared with prior guidance of $845 million to $855 million2
Revised full-year 2026 adjusted EBITDA guidance
$86 million to $88 million non-GAAP adjusted EBITDA guidance, compared with prior guidance of $95 million to $98 million3
Cash, cash equivalents and restricted cash
$86.9 million at September 30, 2026, compared with $104.4 million at June 30, 20269
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$207.86M$205.63M$196.61M$184.01M
Net Income-$6.07M-$22.80M-$27.39M-$28.86M
EPS Diluted-$0.15-$0.57-$0.71-$0.77

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR